Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Emergence of Predictive Metabolomic Biomarkers of Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer.

NCT07847398 is registered in ClinicalTrials.gov with Centre Antoine Lacassagne as lead sponsor.

NCT NCT07847398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07847398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Emergence of Predictive Metabolomic Biomarkers of Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer.
Lead sponsor
Centre Antoine Lacassagne
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
May 31, 2029
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

triple-negative breast cancer (tnbc), stage ii-iii